Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) EBT (2019 - 2025)

Historic EBT for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$39.1 million.

  • Legend Biotech's EBT rose 6767.78% to -$39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.5 million, marking a year-over-year decrease of 18086.92%. This contributed to the annual value of -$158.1 million for FY2024, which is 3030329.31% down from last year.
  • As of Q3 2025, Legend Biotech's EBT stood at -$39.1 million, which was up 6767.78% from -$124.8 million recorded in Q2 2025.
  • Legend Biotech's EBT's 5-year high stood at $59.8 million during Q1 2024, with a 5-year trough of -$407.2 million in Q4 2021.
  • Over the past 5 years, Legend Biotech's median EBT value was -$91.6 million (recorded in 2021), while the average stood at -$91.8 million.
  • As far as peak fluctuations go, Legend Biotech's EBT tumbled by 3385875.4% in 2022, and later skyrocketed by 2769379.34% in 2024.
  • Over the past 5 years, Legend Biotech's EBT (Quarter) stood at -$407.2 million in 2021, then skyrocketed by 66.67% to -$135.7 million in 2022, then skyrocketed by 99.89% to -$146812.0 in 2023, then surged by 27693.79% to $40.5 million in 2024, then tumbled by 196.45% to -$39.1 million in 2025.
  • Its EBT stands at -$39.1 million for Q3 2025, versus -$124.8 million for Q2 2025 and -$99.1 million for Q1 2025.